Results of a multicentre European survey in 1991 of metronidazole resistance inHelicobacter pylori

  • European Study Group on Antibiotic Susceptibility of Helicobacter pylori


In 1991 a multicentre survey on the prevalence of metronidazole resistance inHelicobacter pylori in vitro was carried out in 12 hospitals in 11 different European countries. The susceptibility ofHelicobacter pylori to metronidazole was determined in each centre by measuring the MIC on agar with the PDM E-test (AB Biodisk) according to a standard procedure. Overall, 122 of 443 (27.5 %) strains tested were resistant to metronidazole (MIC>8 µg/ml). The level of resistance to metronidazole varied markedly between centres (from 7 % to 49 %) and was found to be substantially higher in Africans and other non-Caucasian subjects than in natives from European countries. The overall rate of resistance to metronidazole was higher in females (34.7 %) than in males (23.9 %), and varied according to the age group, being highest among women aged 20 to 39 (50 %). Previous use of metronidazole was reported in only 16 patients, 11 of whom (68.8 %) harboured resistantHelicobacter pylori strains. Although differences in the rate of metronidazole resistance inHelicobacter pylori most probably relate to variations in use of this drug in different populations, such use may frequently go unrecognized. This study emphasises the importance of monitoring the drug resistance ofHelicobacter pylori on a local basis. Standardisation of the methods for testing the susceptibility ofHelicobacter pylori in vitro is clearly needed for this purpose.


Internal Medicine Agar European Country Standard Procedure Drug Resistance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Marshall BJ, Goodwin CS, Warren JR, Murray R, Blincow ED, Blackbourn SJ, Philips M, Waters TE, Sanderson CR Prospective double-blind trial of duodenal ulcer relapse after eradication ofCampylobacter pylori. Lancet 1988, ii: 1439–1442.Google Scholar
  2. 2.
    Rauws EAJ, Tytgat GNJ Cure of duodenal ulcer associated with eradication ofHelicobacter pylori. Lancet 1990, 335: 1233–1235.Google Scholar
  3. 3.
    Axon ATR Helicobacter pylori: effect on peptic ulcer disease. Journal of Gastroenterology and Hepatology 1991, 6: 131–137.Google Scholar
  4. 4.
    Becx MC, Janssen AJ, Claesener HA, de Koning RW Metronidazole-resistantHelicobacter pylori. Lancet 1990, 335: 539–540.Google Scholar
  5. 5.
    Glupczynski Y, Burette A, De Koster E, Nyst JF, Deltenre M, Cadranel S, Bourdeaux L, DeVos D Helicobacter pylori and metronidazole resistance. Lancet 1990, 335: 976–977.Google Scholar
  6. 6.
    Glupczynski Y, Burette A Drug therapy forHelicobacter pylori infection: problems and pitfalls. American Journal of Gastroenterology 1990, 85: 1545–1551.Google Scholar
  7. 7.
    Weil J, Bell GD, Powell K, Jobson R, Trowell JE, Gant P, Jones PH Helicobacter pylori and metronidazole resistance. Lancet 1990, 336: 1445.Google Scholar
  8. 8.
    Logan RPH, Gummett PA, Misiewicz JJ, Karim QN, Walker MM, Baron JH One week eradication regimen forHelicobacter pylori. Lancet 1991, 338: 1249–1252.Google Scholar
  9. 9.
    Rautelin H, Seppälä K, Renkonen OV, Vainio U, Kosunen TU Role of metronidazole resistance in therapy ofHelicobacter pylori infection. Antimicrobial Agents and Chemotherapy 1992, 36: 163–166.Google Scholar
  10. 10.
    Goodwin CS, Marshall BJ, Blincow ED, Wilson DH, Blackbourn S, Philips M Prevention of nitroimidazole resistance inCampylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. Journal of Clinical Pathology 1988, 41: 207–210.Google Scholar
  11. 11.
    Westblom TU Laboratory diagnosis and handling ofHelicobacter pylori. In: Marshall BJ, McCallum RW, Guerrant RL (ed):Helicobacter pylori in peptic ulceration and gastritis. Blackwell Scientific Publications, Boston, 1991, p. 81–91.Google Scholar
  12. 12.
    Glupczynski Y, Labbé M, Hansen W, Crokaert F, Yourassowsky E Evaluation of the E test for quantitative antimicrobial susceptibility testing ofHelicobacter pylori. Journal of Clinical Microbiology 1991, 29: 2072–2075.Google Scholar
  13. 13.
    National Committee for Clinical Laboratory Standards Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard M11-A2. NCCLS, Villanova, PA, 1990.Google Scholar
  14. 14.
    Kramer MS Statistical inference for categorical variables. In: Kramer MS (ed): Clinical epidemiology and biostatistics: a primer for clinical investigators and decision-makers. Springer Verlag, Berlin, 1988, p. 165–186.Google Scholar
  15. 15.
    Graham DY, Börsch GM The who's and when's of therapy forHelicobacter pylori. American Journal of Gastroenterology 1990, 85: 1552–1555.Google Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 1992

Authors and Affiliations

  • European Study Group on Antibiotic Susceptibility of Helicobacter pylori

There are no affiliations available

Personalised recommendations